What records are connected here?
- Evidence lanes
- 3
- Source years
- 20
- Drugs@FDA applications
- 15
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsHormones · Bone and growth
Calcitonin salmon is a synthetic version of the hormone calcitonin found in salmon, and the active ingredient in Miacalcin.1,2 Its U.S. label covers symptomatic Paget’s disease of bone and postmenopausal osteoporosis when other treatments are not suitable, and high blood calcium. The label states that it has not been shown to reduce fractures.1 The label warns that a meta-analysis of 21 clinical trials suggests a higher risk of cancer in people treated with calcitonin salmon, and says the need for continued use should be re-evaluated periodically.1
| What it is | A calcitonin receptor agonist that acts mainly on bone. The label states that salmon calcitonin acts like mammalian calcitonins but is more potent and longer-lasting.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Miacalcin under NDA 017808 with an original approval date of July 3, 1986. The cited label has no boxed warning.1,2 |
| Human evidence | Small open-label and randomized studies from its original approvals, described in the label, which states there is no evidence it lowers the risk of osteoporotic fracture.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Calcitonin salmon is a lab-made form of the calcitonin hormone of salmon. Calcitonin is a peptide hormone that slows the breakdown of bone.1
In the United States it is the active ingredient of Miacalcin, approved under NDA 017808, according to Drugs@FDA. The label gives 1975 as the year calcitonin salmon was first approved in the United States.1,2
The label states that calcitonin salmon is a calcitonin receptor agonist that acts primarily on bone, with direct effects on the kidney and digestive tract also recognized.1
The label also states that calcitonin’s role in normal human bone physiology is still not completely understood, although calcitonin receptors are found on the cells that break down and build bone.1
In open-label Paget’s disease trials of several months to two years with historical controls, blood and urine markers of bone turnover improved by more than 30% in about two-thirds of patients, and bone pain improved in a similar share, according to the label.1
In two randomized, open-label osteoporosis studies, total body calcium rose at one year and then trended down. New spinal fractures were similar: 6 with calcitonin salmon and 5 in the control group in year one, and 7 in each in year two.1
The label states that no evidence currently shows it decreases the risk of osteoporotic fracture, and that a controlled study stopped early failed to show any benefit on fracture rate.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Miacalcin, application NDA 017808, with an original approval date of July 3, 1986.2
The Miacalcin label cited here (DailyMed SPL version 9, published June 19, 2026) states that it is indicated for symptomatic Paget’s disease of bone and postmenopausal osteoporosis when alternative treatments are not suitable, and for high blood calcium.1
The label has no boxed warning. Its warnings include serious allergic reactions including fatal anaphylaxis, low blood calcium, a possible increase in cancer risk, and antibodies that may cause a loss of response.1
Whether it prevents fractures: the label states that fracture reduction has not been demonstrated.1
Its effect on spinal bone density beyond one year, which the label states no adequate controlled trial has examined.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Calcitonin salmon: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Calcitonin salmon are a bounded selection, not every registration or paper about Calcitonin salmon. For the years before Calcitonin salmon was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Calcitonin salmon as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Calcitonin salmon in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Miacalcin for Paget’s disease, high blood calcium and osteoporosis. The label describes small open-label and randomized studies and states that fracture reduction has not been demonstrated. It warns of a possible increase in cancer risk.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Miacalcin for Paget’s disease, high blood calcium and osteoporosis. The label describes small open-label and randomized studies and states that fracture reduction has not been demonstrated. It warns of a possible increase in cancer risk.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Regulatory · source date October 29, 2026
Drugs@FDA application ANDA216996↗Added to PeptideScanner November 15, 2026Literature metadata · added November 16, 2026
Salmon calcitonin prescribing for acute phantom limb pain after amputation.↗Source date October 23, 2026Literature metadata · added November 16, 2026
Production of biologically active recombinant salmon calcitonin in Escherichia coli and fish cell line.↗Source date May 24, 2025Literature metadata · added November 16, 2026
Tuning the double lipidation of salmon calcitonin to introduce a pore-like membrane translocation mechanism.↗Source date May 25, 2024PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
4 of 4 selected trial records include at least one phase value; 4 of 4 include a status value in the retained structured contract.
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PubMed lists PMID 11045148 in Vnitrni lekarstvi as Clinical Trial, Journal Article, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 18071651 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Review, with publication-date metadata of 2007-12-11 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 2137363 in Calcified tissue international as Comparative Study, Journal Article, Review, with publication-date metadata of 1990 (year precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span April 17, 1978 to October 29, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 216996 with status AP dated 2026-10-29, and names calcitonin salmon among the application record's active ingredients.↗
Literature metadata
PubMed lists PMID 42919113 in Anaesthesia as Journal Article, with publication-date metadata of 2026-10-22 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 215864 with status AP dated 2026-03-04, and names calcitonin salmon among the application record's active ingredients.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 216294 with status AP dated 2025-09-26, and names calcitonin salmon among the application record's active ingredients.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 219196 with status AP dated 2025-07-09, and names calcitonin salmon among the application record's active ingredients.↗
Literature metadata
PubMed lists PMID 39862273 in Archives of microbiology as Journal Article, with publication-date metadata of 2025-01-25 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 212675 with status AP dated 2024-12-05, and names calcitonin salmon among the application record's active ingredients.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 213766 with status AP dated 2024-09-20, and names calcitonin salmon among the application record's active ingredients.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03935984 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03812991 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-06-11, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.↗
Literature metadata
PubMed lists PMID 38713958 in Journal of colloid and interface science as Journal Article, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 215715 with status AP dated 2024-04-11, and names calcitonin salmon among the application record's active ingredients.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
FDA Global Substance Registration System · Official source · Source checked November 15, 2026